Clinical Trials
21 trialsNCT02314169 2026-05-12
Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05551117 2026-02-09
Tamarack
MacroGenics
Phase 2 Terminated
NCT04505553 2026-01-21
Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer
University of Washington
Phase 2 Completed
NCT00324415 2025-05-30
Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer
AIDS Malignancy Consortium
Phase 2 Completed
NCT03018418 2024-09-19
Proton Therapy in Reducing Toxicity in Anal Cancer
University of Cincinnati
Phase 2 Active not recruiting
NCT03439085 2024-07-09
DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT04066894 2023-08-14
Sacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal Incontinence in Patients With Locally Advanced Rectal Cancer or Other Pelvic Cancer, the RESTORE Study
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT03499795 2023-07-14
VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2
Inovio Pharmaceuticals
Phase 2 Completed
NCT00316888 2023-06-29
Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Anal Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT03690921 2023-06-29
Linear Energy Transfer (LET)-Optimized Intensity Modulated Proton Therapy (IMPT) as a Component of Definitive Chemoradiation for Newly Diagnosed Squamous Cell Carcinoma of the Anal Canal: a Feasibility Trial
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02919969 2023-06-12
Pembrolizumab in Metastatic Anal Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00093379 2023-04-18
Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03427411 2023-03-28
M7824 in Subjects With HPV Associated Malignancies
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02399813 2023-03-20
A Phase 2 Study of Axalimogene Filolisbac (ADXS11-001) in Participants With Carcinoma of the Anorectal Canal
Advaxis, Inc.
Phase 2 Completed
NCT01209325 2020-08-11
Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males
AIDS Malignancy Consortium
Phase 2 Completed
NCT00622440 2020-04-24
AIJP
University of California, San Francisco
Phase 2 Completed
NCT01717391 2019-03-26
[F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers
University of Iowa
Phase 2 Completed
NCT00423293 2019-02-27
Intensity-Modulated Radiation Therapy, Fluorouracil, and Mitomycin C in Treating Patients With Invasive Anal Cancer
Radiation Therapy Oncology Group
Phase 2 Completed
NCT01585428 2018-03-07
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00903396 2017-11-24
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Terminated
NCT00550589 2015-12-21
Cidofovir in Treating HIV-Infected Patients With High-Grade Squamous Intraepithelial Lesions of the Skin Near the Anus
AIDS Malignancy Consortium
Phase 2 Completed